气喘吁吁的后果：新冠后肺纤维化

Breathless Aftermath: Post-COVID-19 Pulmonary Fibrosis.

作者信息

Muthiah Dharanya, Vaddadi Kishore, Liu Lin

机构信息

Oklahoma Center for Respiratory and Infectious Diseases, Oklahoma State University, Stillwater, OK 74074, USA.

The Lundberg- Kienlen Lung Diseases and Infection Laboratory, Department of Physiological Sciences, Oklahoma State University, Stillwater, OK 74074, USA.

出版信息

Viruses. 2025 Aug 9;17(8):1098. doi: 10.3390/v17081098.

DOI:10.3390/v17081098

PMID:40872813

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC12390685/

Abstract

A significant number of individuals recovering from COVID-19 continue to experience persistent symptoms, collectively referred to as Post-Acute Sequelae of SARS-CoV-2 infection (PASC), or long COVID. Among these complications, post-COVID-19 pulmonary fibrosis (PC19-PF) is one of the most severe long-term outcomes, characterized by progressive lung scarring, chronic respiratory impairment, and reduced quality of life. Despite the increasing prevalence of PC19-PF, its underlying mechanisms remain poorly understood. In this review, we provide a comprehensive overview of PC19-PF, including its epidemiology, clinical manifestations, diagnostic strategies, and mechanistic insights. Additionally, we highlight the shared pathways between PC19-PF and other fibrotic lung diseases and discuss emerging therapeutic strategies. This review consolidates emerging insights from both clinical and experimental studies to advance our understanding of PC19-PF pathogenesis and guide the development of mechanism-based therapeutic approaches.

摘要

大量新冠康复者仍持续出现症状，统称为新冠病毒感染后急性后遗症（PASC），即长新冠。在这些并发症中，新冠后肺纤维化（PC19-PF）是最严重的长期后果之一，其特征是进行性肺瘢痕形成、慢性呼吸功能损害和生活质量下降。尽管PC19-PF的患病率不断上升，但其潜在机制仍知之甚少。在本综述中，我们全面概述了PC19-PF，包括其流行病学、临床表现、诊断策略和机制见解。此外，我们强调了PC19-PF与其他纤维化肺病之间的共同途径，并讨论了新兴的治疗策略。本综述整合了临床和实验研究的新见解，以增进我们对PC19-PF发病机制的理解，并指导基于机制的治疗方法的开发。